Welcome to LookChem.com Sign In|Join Free

CAS

  • or

19658-64-1

Post Buying Request

19658-64-1 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

19658-64-1 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 19658-64-1 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 1,9,6,5 and 8 respectively; the second part has 2 digits, 6 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 19658-64:
(7*1)+(6*9)+(5*6)+(4*5)+(3*8)+(2*6)+(1*4)=151
151 % 10 = 1
So 19658-64-1 is a valid CAS Registry Number.

19658-64-1SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 19, 2017

Revision Date: Aug 19, 2017

1.Identification

1.1 GHS Product identifier

Product name ethyl 6-oxo-5H-[1,3]dioxolo[4,5-g]quinoline-7-carboxylate

1.2 Other means of identification

Product number -
Other names ETHYL 6-HYDROXY-[1,3]DIOXOLO[4,5-G]QUINOLINE-7-CARBOXYLATE

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:19658-64-1 SDS

19658-64-1Downstream Products

19658-64-1Relevant articles and documents

Synthesis of new quinoline-piperonal hybrids as potential drugs against Alzheimer’s disease

Brum, Juliana de Oliveira C.,Neto, Denise Cristian F.,de Almeida, Joyce Sobreiro F. D.,Lima, Josélia Alencar,Kuca, Kamil,Fran?a, Tanos Celmar C.,Figueroa-Villar, José D.

, (2019)

Six quinoline-piperonal hybrids were synthesized and evaluated as potential drugs against Alzheimer’s disease (AD). Theoretical analysis of the pharmacokinetic and toxicological properties of the compounds suggest that they present good oral bio-availability and are also capable of penetrating the blood–brain barrier, qualifying as leads for new drugs against AD. Evaluation of their inhibitory capacity against acetyl-and butyrilcholinesterases (AChE and BChE) through Ellmann’s test showed that three compounds present promising results with one of them being capable of inhibiting both enzymes. Further docking studies of the six compounds synthesized helped to elucidate the main interactions that may be responsible for the inhibitory activities observed.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 19658-64-1